Features Screener Stocks Charts
Sign In Sign Up

Gufic Biosciences Cash Flow Statement

NSE:GUFICBIO | PHARMACEUTICALS

Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.

View Plans

Cash Flow Insights

Cash Conversion

1.76x

GUFICBIO's operating cash flow exceeded net income in FY 2025, indicating earnings are backed by actual cash generation.

Free Cash Flow

₹470.42M

GUFICBIO's free cash flow was ₹470.42M in FY 2025, up 139.2% from FY 2024.

Dividend Coverage

46.9x

GUFICBIO's free cash flow covered dividends 46.9x in FY 2025, leaving room for reinvestment or debt reduction.

CapEx Intensity

61.6%

Capital expenditure consumed 61.6% of operating cash flow in FY 2025 for GUFICBIO, typical of capital-intensive industries.

2-year GUFICBIO cash flow snapshot

Hover the chart icon for YoY change.

FY 2024 - FY 2025
Item Chart 2024 2025
Net Income 861.36M 696.49M
Cash flow Operating Activities -74.57M 1.23B
Investments in PPE -1.13B -755.26M
Cash flow Investing Activities -1.02B -707.77M
Dividend Paid -9.72M -10.03M
Cash flow Financing Activities 823.81M -372.04M
Cash at beginning of period 286.02M 11.37M
Cash at end of period 11.37M 157.23M
Free Cash Flow -1.20B 470.42M

Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025